NFKB1 and non-small cell lung carcinoma: Our finding that silencing URGCP in NSCLC cells dramatically inhibits IKK activity, causing the suppression of NF-kB signaling, suggests that URGCP may be a novel potential therapeutic agent for interventional strategies.